Galimedix Therapeutics reported a next-generation oral prodrug with significantly improved pharmacokinetics, including enhanced absorption and higher systemic exposure, at AD/PDM 2026 for Alzheimer’s disease.
Written by: Katherashala Dharan Kumar, PharmD
Reviewed By: Pharmacally Editorial Team
Galimedix Therapeutics presented preclinical data highlighting an improved pharmacokinetic (PK) profile for a next-generation oral prodrug of its amyloid-beta (Aβ) aggregation modulator GAL-201 for the treatment of Alzheimer’s disease. The findings were shared at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD 2026) in Copenhagen, Denmark.
The new prodrug demonstrated rapid absorption and significantly higher peak plasma concentrations compared with the parent compound, indicating improved systemic exposure. The superior PK profile may enable significantly reduced oral doses, an important advantage for therapies requiring long-term administration in Alzheimer’s disease.
“The data presented at AD/PD 2026 demonstrate the rapid absorption and significantly higher peak plasma concentrations of this new prodrug compared to the parent compound,” said Hermann Russ, Co-founder and Chief Scientific Officer of Galimedix. “These characteristics support its potential as an oral Aβ-targeting development candidate that could enable improved efficacy and more patient-friendly dosing for the long-term treatment of Alzheimer’s disease.”
References
Galimedix Therapeutics. Galimedix Therapeutics presents strong pharmacokinetic profile of next-generation oral Alzheimer’s candidate at AD/PD™ 2026. 2026. https://galimedix.com/article/galimedix-therapeutics-presents-strong-pharmacokinetic-profile-of-next-generation-oral-alzheimers-candidate-at-ad-pd-2026/
Katherashala Dharan Kumar, PharmD A dedicated Clinical Researcher with expertise in medical and scientific writing clinical trials, drug safety, and healthcare innovation. Actively contributes to research publications and clinical documentation focused on improving patient outcomes through evidence-based practices and ethical research standards. Believe that every complex data point has a human story waiting to be told. Focusing on providing actionable insights for clinical research.